Equillium, Inc. (EQ) vs Rani Therapeutics Holdings, Inc. (RANI)

Equillium, Inc. and Rani Therapeutics Holdings, Inc. are both Biotechnology companies. Equillium, Inc. and Rani Therapeutics Holdings, Inc. are of similar size ($109.1M and $107.3M). Rani Therapeutics Holdings, Inc. grew revenue faster over the last twelve months: 78.7% against 13.9%. Equillium, Inc. has the higher net margin (0.00% vs −597.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Equillium, Inc. leads on 11 and Rani Therapeutics Holdings, Inc. on 3.

Valuation

Metric EQ RANI Biotechnology median
P/E n/m n/m 7.88
P/S 4.54 28.17 11.47
P/B 3.33 2.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 3.18 20.72 10.73
Earnings yield (11.98%) (35.53%) (28.84%)
Free cash flow yield (10.75%) (14.30%) (23.03%)

Profitability

Metric EQ RANI Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (652.78%) 0.00%
Net margin 0.00% (596.97%) 0.00%
Free cash flow margin 0.00% (402.83%) 0.00%
Return on equity (58.98%) (155.24%) (57.72%)
Return on assets (50.68%) (77.54%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EQ RANI Biotechnology median
Revenue growth (TTM) 13.89% 78.73% 5.64%
EPS growth (last fiscal year) (69.57%) 57.14% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EQ RANI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 23.40 5.31 4.73
Net debt to EBITDA 1.29 1.33 0.96

Dividend

Metric EQ RANI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric EQ RANI Biotechnology median
Market cap 109.06m 107.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack